Navigation Links
Pharmatech Oncology Launches New Data Management Business Unit
Date:4/24/2009

DENVER, April 24 /PRNewswire/ -- Pharmatech Oncology, Inc., a Research Management Organization (RMO) headquartered in Denver, Colorado, announces the launch of their Data Management business unit to the bioscience and pharmaceutical industries. The Pharmatech Oncology Data Management business unit is branded as C(3)DM (Customized, Consistent, and Clinical Data Management). The Data Management business unit maintains and processes data for a broad range of clinical trials in various therapeutic areas, not only in the fields of oncology and hematology.

In managing clinical data projects, the C(3)DM business unit has built a solid data system platform focused around the EDC (electronic data capture) solution TrialMaster(TM) from OmniComm Systems, Inc.(TM) The platform is designed to be customized to incorporate all of the clinical data aspects involved in each individual clinical trial. "The Data Management team has worked extremely hard over the last few months to develop a fully-integrated solution for data capture and patient accrual for a lymphoma trial. Our unique platform gives clients access to a wide-range of capabilities by having their data managed through a trusted and reliable source, while also having our clinical sites trained by the creators of the system," states Jason Lones, Clinical Data Manager.

The data management business unit focuses on customized data capture solutions for any clinical development marketplace. Data integrity throughout the data management process is assured by following FDA regulations, adhering to industry standard GCPs, and maintaining 21CFR Part 11 compliance.

About Pharmatech Oncology:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. The Data Management business entity manages data for all types of clinical research, along with in-house trials focused in oncology and hematology. Through an organized research network, the Company focuses on the development and utilization of therapeutic products among sponsors, investigators, and patients. For more information about Pharmatech Oncology, please visit www.pharmatechoncology.com.

About OmniComm:

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Chicago, Germany, Tula, Russia, California, New York, North Carolina, Tennessee, Massachusetts and Georgia.

Key Words: Cancer, Clinical Trials, Contract Research, Data Management, Network, Oncology, Patients, Research, Site Management


'/>"/>
SOURCE Pharmatech Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WuXi PharmaTech Schedules Fourth Quarter 2008 Earnings Release on Thursday, March 26, 2009
2. WuXi PharmaTech Announces CFO Benson Tsang to Leave Company; COO Edward Hu Named Acting CFO
3. WuXi PharmaTech Honored on the Deloitte Technology Fast 500 Asia Pacific 2008 List for the Fifth Consecutive Year
4. WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board
5. WuXi PharmaTech to Present at 20th Annual Piper Jaffray Healthcare Conference
6. WuXi PharmaTech Expands Collaboration for Fully Integrated Services
7. WuXi PharmaTech Announces Second Quarter 2008 Results
8. WuXi PharmaTech (NYSE: WX) Appoints Mr. Steven M. Hutchins as VP of Business Development
9. Dr. Richard M. Soll Joined WuXi PharmaTech (NYSE: WX) as VP of Medicinal Chemistry
10. WuXi PharmaTech 2007 Annual Report Available Online
11. The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream that really works. ... be incorporated into the post-surgical treatment plans of a variety of other procedures including, ... is very effective for bruising and causes a rapid resolution of bruising and inflammatory ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Seema Daulat, a native Texan and University ... Lamar location as of July 13, 2016. , Dr. Daulat earned her Doctorate of ... she regularly volunteered at the Agape Clinic serving Dallas’ underprivileged community. , Following medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology: